Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition

Julian Taugner1 · Lukas Käsmann1,2 · Monika Karin1 · Chukwuka Eze1 · Benedikt Flörsch1 · Julian Guggenberger1 · Minglun Li1,3 · Amanda Tufman2,4 · Niels Reinmuth5 · Thomas Duell5 · Claus Belka1,2,3 · Farkhad Manapov1,2,3

Received: 30 April 2021 / Accepted: 22 June 2021 / Published online: 5 August 2021
© The Author(s) 2021

Summary

Background. The present study evaluates outcome after chemoradiotherapy (CRT) with concurrent and/or sequential Programmed Cell Death 1 (PD-1) or Ligand 1 (PD-L1) immune checkpoint inhibition (CPI) for inoperable stage III NSCLC patients depending on planning target volume (PTV). Method and patients. Prospective data of thirty-three consecutive patients with inoperable stage III NSCLC treated with CRT and sequential durvalumab (67%, 22 patients) or concurrent and sequential nivolumab (33%, 11 patients) were analyzed. Different PTV cut offs and PTV as a continuous variable were evaluated for their association with progression-free (PFS), local–regional progression-free (LRPFS), extracranial distant metastasis-free (eMFS) and brain-metastasis free-survival (BMFS). Results. All patients were treated with conventionally fractionated thoracic radiotherapy (TRT); 93% to a total dose of at least 60 Gy, 97% of patients received two cycles of concurrent platinum-based chemotherapy. Median follow-up for the entire cohort was 19.9 (range: 6.0–42.4) months; median overall survival (OS), LRFS, BMFS and eMFS were not reached. Median PFS was 22.8 (95% CI: 10.7–42.4) months. Patients with PTV $\geq$ 900ccm had a significantly shorter PFS (6.9 vs 22.8 months, $p=0.020$) and eMFS (8.1 months vs. not reached, $p=0.003$). Furthermore, patients with PTV $\geq$ 900ccm and stage IIIC disease (UICC-TNM Classification 8th Edition) achieved a very poor outcome with a median PFS and eMFS of 3.6 vs 22.8 months ($p<0.001$) and 3.6 months vs. not reached (p = 0.001), respectively. PTV as a continuous variable also had a significant impact on eMFS ($p=0.048$). However, no significant association of different PTV cut-offs or PTV as a continuous variable with LRPFS and BMFS could be shown. The multivariate analysis that was performed for PTV $\geq$ 900ccm and age (≥ 65 years), gender (male), histology (non-ACC) as well as T- and N-stage (T4, N3) as covariates also revealed PTV $\geq$ 900ccm as the only factor that had a significant correlation with PFS (HR: 5.383 (95% CI:1.263–22.942, $p=0.023$)). Conclusion. In this prospective analysis of inoperable stage III NSCLC patients treated with definitive CRT combined with concurrent and/or sequential CPI, significantly shorter PFS and eMFS were observed in patients with initial PTV $\geq$ 900ccm.

Keywords Chemoradiotherapy · Checkpoint inhibition · Non-small cell lung cancer · Tumor volume · Prediction
**Introduction**

Lung cancer is the most frequent cause of cancer-related mortality worldwide [1]. Inoperable, locally advanced lung cancer is a very heterogeneous disease in terms of macroscopic tumor extent and patient prognosis. Historically only ten to thirty percent of these patients survive five years after multimodal treatment [2–4].

Regarding inoperable stage III NSCLC, the implementation of CPI as one of the key components of a multimodal approach has already led to an unprecedented improvement in progression-free survival (PFS) and OS [5–8]. In particular, the ground-breaking PACIFIC phase III trial demonstrated a three-year survival rate of 57% and a median PFS of 16.8 months [9, 10]. In addition, the first clinical reports on chemoradioimmunotherapy have confirmed the PACIFIC findings concerning patient outcome [7, 11–13].

Prior to the actual use of durvalumab maintenance therapy after chemoradiotherapy (CRT), planning target volume (PTV) has been considered an important prognosticator for patient outcome and treatment-related toxicity in inoperable stage III NSCLC [14–16]. Two retrospective mono-institutional analyses, in particular, reported that a PTV cut-off of 700ccm had a significant negative impact on patient outcome after conventional CRT [17, 18].

In the present prospective study, we evaluated the impact of PTV on PFS, local–regional progression-free (LRPFS), extracranial distant metastasis-free (eMFS) as well as brain-metastasis free-survival (BMFS) after CRT with concurrent and/or sequential Programmed Cell Death 1 (PD-1) or Ligand 1 (PD-L1) immune checkpoint inhibition (CPI).

**Methods**

This study included data of 33 prospectively enrolled patients who received concurrent and/or sequential conventionally fractionated CRT and CPI treatment as part of a multimodal approach for inoperable UICC 8th edition stage IIIA-C NSCLC between 2017 and 2020. More precisely, CPI consisted of either sequential administration of durvalumab or conventional and sequential administration of nivolumab. All patients gave informed consent to the treatment and the prospective collection of their data for research purposes. The local ethics committee agreed to the analysis and publication of the patients’ data (17–230). All patients enrolled, were treated at a single tertiary cancer center, with either the PD-1 inhibitor nivolumab in the ETOP 6–14 NICOLAS phase II study (33%, 11 patients) or the PD-L1 inhibitor durvalumab according to the PACIFIC trial (67%, 22 patients) as part of a maintenance therapy and are henceforth referred to as the NICOLAS and PACIFIC subgroup.

Prior to treatment, radiographic imaging was performed using positron emission tomography (PET)-CT in 32 (97%) patients and CT in 1 (3%) patient. Cranial contrast-enhanced MRI was performed in 31 (94%) patients before starting treatment, two patients (6%) received contrast-enhanced cranial CT. All patients underwent pulmonary function testing and received routine blood work in order to assess kidney and liver function as well as a complete blood count. In all cases, multimodal treatment was reviewed in the multidisciplinary tumor boards. The therapeutic approach was discussed with each individual patient. Patients with an initial performance status ECOG ≥ 2 or poor lung function (DLCO < 40%, FEV1 < 1 L or on long-term oxygen supply) were excluded.

Based on conventional planning-CT as well as PET-CT scans in the treatment position, conventionally fractionated thoracic radiotherapy (TRT) was planned and delivered while patients were supine with their arms positioned overhead in a dedicated positioning and immobilization device - WingSTEP™ (Innovative Technologie Völp, Innsbruck, Austria). The target volumes were defined according to the European Society for Therapeutic Radiology and Oncology-Advisory Committee on Radiation Oncology Practice (ESTRO-ACROP) guidelines published in 2018 [19]. If patients were pre-treated with induction chemotherapy, only the residual primary tumor volume was contoured as gross tumor volume (GTV) and lymph node stations involved before chemotherapy were included in the clinical target volume (CTV). PTVs were generated by adding axial/cranio-caudal margins of 6/9 mm to the CTVs.

TRT was administered to the primary tumor and involved lymph nodes up to a median total dose of 63.6 Gy in 2.12 Gy single dose fractions. Radiation was delivered on a Linear accelerator (LINAC) with megavoltage capability using Volumetric Modulated Arc Therapy (VMAT) in all patients. Image-guidance was performed with a cone-beam CT at least twice a week.

All patients received a platinum-based doublet; 32 patients (97%) were treated concurrently with TRT and one patient (3%) was treated sequentially. Seventeen patients (51.5%) received at least one cycle of induction chemotherapy prior to TRT.

Durvalumab maintenance treatment at a dose of 10 mg/kg every two weeks for up to 12 months, until disease progression or the evidence of unacceptable toxicity was administered in 22 (67%) patients according to the PACIFIC trial [5, 9].

Eleven (33%) patients were enrolled in the phase II NICOLAS-trial (ETOP 6–14) and treated with concurrent nivolumab, chemotherapy and TRT, followed by nivolumab maintenance treatment every four weeks up to one year, until disease progression or the onset of unacceptable toxicity [6].

In the first two years after therapy, routine blood work, lung function testing, clinical examinations and CT or PET-CT
scans were arranged every 3 months, thereafter twice a year. If clinically indicated, cranial contrast-enhanced MRI and bone-scintigraphy were additionally performed. Response was assessed according to RECIST 1.1. Local and local–regional progression (LP) along with new extracranial distant metastases (eDM) and brain metastases (BM) were documented with CT, PET-CT or MRI scans. Cytological or histological confirmation of progressive disease was not obligatory. All volumetric parameters were extracted from the radiation treatment plans. Median follow-up was calculated as the median time to loss or end of follow-up after the last day of radiotherapy in patients who were not documented as deceased. Progression-free survival (PFS) was defined as the time from the end of TRT until the occurrence of either disease progression or death. Overall survival (OS) was also calculated from the end of TRT. Time to death or metastasis (TTDM) included extracranial distant metastases (eDM) and brain metastases (BM) from the end of TRT. Univariate analysis of OS, PFS, LRPFS, eMFS and BMFS was carried out with following parameters: age, gender, T- and N-stage, histology, PD-L1 status and different PTVs. All statistics were performed using IBM SPSS version 25 (IBM, Armonk, New York, USA).

### Results

The entire cohort consisted of 33 consecutive patients with inoperable UICC 8th edition stage IIIA-C NSCLC. A summary of patients’ characteristics is shown in Table 1.

The median age was 62.0 (range 43.8–76.9) years with 15 patients (45.5%) older than 65 years. Nine patients (27%) were female and 24 (73%) were male. In the histological evaluation, 13 (39%) patients had squamous-cell carcinoma (SCC), 18 (55%) had adenocarcinoma (AC) and in 2 (6%) patients the tumor was classified as not otherwise specified (NOS). PD-L1 status was assessed in 28 (84.8%) patients prior to multimodal treatment. 26 (93%) of patients tested were PD-L1 > 1% (median 60%). All 33 patients completed conventional fractionated radiotherapy to a total dose ≥60.0 Gy (median total dose: 63.6 Gy). Median PTV was 675.6 (range: 204.5–1234.5) ccm. Concurrent CRT was performed in 32 (97%) patients and one (3%) patient received sequential chemotherapy and TRT. The predominant concurrent chemotherapy regimen administered in 27 (82%) patients consisted of cisplatin and vinorelbine. Eleven (33%) patients were treated within the NICOLAS trial and received concomitant nivolumab (4x360 mg Q3W) during CRT and thereafter (480 mg Q4W) for up to one year (median cycles: 9, range: 3–14). The other 22 (67%) patients received durvalumab maintenance therapy for up to 24 cycles after the end of CRT based on the PACIFIC trial (10 mg/m² Q2W; median cycles: 14, range: 2–24).

| Table 1 Patient and treatment characteristics |
|-----------------------------------------------|
| N (%)                                         |
| Total                                         | 33 (100) |
| Age median years > 65 years                   | 62.0     |
| Gender                                        |
| Male                                          | 24 (72.6) |
| Female                                        | 9 (27.4)  |
| T-stage                                       |
| 1                                             | 7 (21.2)  |
| 2                                             | 8 (24.2)  |
| 3                                             | 15 (45.5) |
| 4                                             |          |
| N-stage                                       |
| 0                                             | 1 (3.0)   |
| 1                                             | 12 (36.4) |
| 2                                             | 14 (42.4) |
| 3                                             |          |
| UICC 8th edition                              |
| IIIA                                           | 16 (48.5) |
| IIIB                                           | 8 (24.2)  |
| IIC                                           |          |
| PTV size                                       |
| ≥900ccm                                       | 675.6    |
| ≥900ccm                                       | 6 (18.2)  |
| Histology                                     |
| Squamous cell carcinoma (SCC)                 | 13 (39.4) |
| Adenocarcinoma (AC)                           | 18 (54.5) |
| Not otherwise specified (NOS)                 | 2 (6.1)   |
| Radiographic imaging                          |
| PET-CT                                        | 32 (97.0) |
| cMRI                                          | 31 (93.9) |
| Treatment                                     |
| Concurrent chemoradiation (CRT)               | 32 (97.0) |
| Induction chemotherapy                        | 17 (51.5) |
| NICOLAS                                       | 11 (33.3) |
| PACIFIC                                       | 22 (66.7) |
| Median Follow-up                              |
| Months after CRT                              |
| OS                                            | 100%     |
| 6-month                                       | 93.3%    |
| 12-month                                      | 87.0%    |
| 18-month                                      |          |
| PFS                                           | 87.5%    |
| 6-month                                       | 67.7%    |
| 12-month                                      | 40.0%    |
| 18-month                                      |          |
| eMFS                                          | 87.5%    |
| 6-month                                       | 74.2%    |
| 12-month                                      | 56%      |
| 18-month                                      |          |

The results were analyzed using IBM SPSS version 25 (IBM, Armonk, New York, USA).
The median follow-up for the entire cohort was 19.9 (range: 6.0–42.4) months, median PFS was 22.8 (95% CI: 10.7–34.8) and median TTDM was 26.3 (95% CI: 3.6–49.0) months whereas median OS, median BMFS as well as eMFS were not reached.

For PFS, no significant difference could be revealed between the NICOLAS and the PACIFIC subgroup, with a median PFS of 22.7 (95%CI:9.1–36.4) months vs not reached (\(p = 0.831\)). The same was true for patients treated with or without induction chemotherapy, with a median PFS of 21.9 months vs not reached (\(p = 0.853\)).

Furthermore, disease stage (UICC 8th edition) had no significant impact on PFS (IIIA: median not reached, IIIB: median 22.8 months, IIIC: median 11.8 months, \(p = 0.810\)). Patients with stage IIIC disease had only a numerical inferior PFS (11.8 vs 22.8 months, \(p = 0.545\)) compared to the rest of the cohort.

No influence of PD-L1 status on PFS could be shown, neither for 0% vs. \(\geq 1\%\) (\(p = 0.764\), 26.3 vs 14.0 months median) nor for <50 vs \(\geq 50\%\) (\(p = 0.459\), 11.0 vs 14.6 months median). No significant impact of patient- (age and gender) and tumor-related (histology, T- and N-stage) characteristics on PFS was documented. For detailed results see Table 2.

However, a significant correlation between PTV and PFS was demonstrated for PTV \(\geq 900\text{ccm}\) with a median PFS of 6.9 (95%CI: 0.3–13.6) vs 22.8 (95%CI:10.0–35.5) months (\(p = 0.020\)). The corresponding 6-, 12- and 18-months PFS-rates were 60%, 20% and 0% compared to 93%, 77% and 48%, respectively (Fig. 2). To further clarify the influence of PTV \(\geq 900\text{ccm}\) as a prognostic cut-off, we also tested it for LRPFS and TTDM: A trend was observed for TTDM with a median TTDM of 8.0 vs 26.3 months (\(p = 0.089\)), but there was no significant impact on LRPFS (13.2 vs. 24.8 months, \(p = 0.064\)). We found no influence of PTV \(\geq 900\text{ccm}\) on BMFS (15.8 vs. 32.5 months, \(p = 0.296\)). However, median eMFS was 8.1 (95%CI: 0.0–17.1) months in patients with PTV \(\geq 900\text{ccm}\) vs no reached with PTV <900ccm (\(p = 0.003\)) Fig. 3. The corresponding 6-, 12- and 18-months eMFS-rates were 60%, 20% and 0% compared to 93%, 85% and 66%, respectively.

Three patients (9%) with PTV \(\geq 900\text{ccm}\) also presented with UICC stage IIIC disease; their median PFS was 3.6 (range 2.7–11.8) months after TRT in contrast to a median PFS of 22.8 (95%CI: 10.3–32.2) months in other patients (\(p < 0.001\)). Their median eMFS was 3.6 months vs not reached (\(p = 0.001\)).

In the multivariate analysis performed for PTV \(\geq 900\text{ccm}\) as well as age (\(\geq 65\) years), gender (male), histology (non-ACC) and T- and N-stage (T4, N3) as covariates, PTV \(\geq 900\text{ccm}\) was the only factor that significantly correlated with PFS (HR: 5.383 (95% CI:1.263–22.942, \(p = 0.023\)).

Moreover, we evaluated PTV as a continuous variable and discovered a significant impact on eMFS (\(p = 0.048\); see Table 3).

| Table 2 Results of the univariate analysis (Log-Rank test) |
|-----------------------------------------------------------|
|                                                            |
| **Entire cohort**                                         |
| N (%)                                                     |
|                                                            |
| **PFS**                                                   |
| \(p\)                                                     |
|                                                            |
| **LRPFS**                                                 |
| \(p\)                                                     |
|                                                            |
| **eMFS**                                                  |
| \(p\)                                                     |
|                                                            |
| Total 33 (100)                                            |
| Age > 65 years 15 (45.5)                                  |
| Gender Male 24 (72.6)                                     |
| T-stage 4 15 (45.5)                                       |
| N-stage 3 14 (42.4)                                       |
| UICC-stage IIIC 8 (24.2)                                 |
| PTV-size \(\geq 900\text{ccm}\) 6 (18.2)                 |
| Histology SCC+NOS 15 (45.5)                               |
| PD-L1-status \(\geq 1\%\) 26 (78.8)                      |
| \(\geq 50\%\) 13 (39.4)                                  |
| Treatment NICOLAS vs. PACIFIC 31 (93.9)                   |
| Induction chemotherapy NICOLAS vs. PACIFIC 11 (33.3) vs. 22 (66.7) |
| Subgroup with UICC stage IIIc and a PTV \(\geq 900\text{ccm}\) 3 (9.1%) p < 0.001 0.123 0.001 |
Discussion

The aim of the present study was to evaluate the role of PTV (including the primary tumor and involved lymph node stations) on disease progression in patients with inoperable stage III NSCLC treated with CRT combined with concurrent and/or sequential CPI. Prospectively collected data of thirty-three patients were analyzed.

In accordance with the current ESTRO-ACROP guidelines for inoperable stage III NSCLC, involved lymph node stations were included in the clinical target volume (CTV). In addition, corresponding safety margins for potential patient positioning and setup errors were added in order to generate a PTV [19]. For the majority of patients, a recent PET-CT was available to delineate the target volume and if induction chemotherapy was administered in advance.

---

| months | 0  | 6  | 12 | 18 |
|--------|----|----|----|----|
| < 900 ccm | 27 / 0 | 25 / 2 | 20 / 6 | 10 / 11 |
| ≥ 900 ccm | 6 / 0 | 3 / 2 | 1 / 4 | 0 / 4 |

Fig. 1  Kaplan–Meier curves of progression-free survival (PFS) for all patients stratified according to the planning target volume (PTV)
imaging before and after induction was carefully considered [20]. Although these results are preliminary due to the limited number of patients and the short follow-up (median 19.9 months), we found a significantly shorter PFS and eMFS in patients with very large PTV $\geq$ 900ccm. For eMFS, a predictive role of PTV as a continuous variable was also revealed. Moreover, the deterioration of PFS and eMFS was more pronounced when PTV $\geq$ 900ccm was combined with stage IIIC disease (UICC 8th edition): In this subgroup PFS was only 3.6 (range: 2.7–11.8) months vs 22.8 (95%CI: 10.3–32.2) months in the rest of the treated cohort and eMFS was 3.6 months vs not reached ($p = 0.001$). Interestingly, a larger PTV was not associated with a significant increase in locoregional recurrences as well as intracranial relapse.

Historically, PTV has been a strong prognosticator regarding patient outcome in inoperable lung cancer. The Radiation Therapy Oncology Group 93–11 Phase I-II dose-escalation study confirmed an inferior PFS and OS for patients with larger tumors. In fact, patients with smaller (≤45cm³) tumors had a longer median survival time (MST) and a better PFS than patients with larger (>45cm³) tumors (29.7 vs 13.3 months, $p < 0.0001$ and 15.8 vs 8.3 months, $p < 0.0001$) [21].

PTV was also validated as an important prognostic factor in the dose-escalation phase III RTOG 0617 study for inoperable stage III NSCLC [15, 16]. The open-label randomized, two-by-two factorial phase III study included 166 patients with unresectable NSCLC stage III treated with CRT between 2007 and 2011. On univariate analysis Bradley et al. indicated that increasing values of GTV and PTV are associated with increased risk of death. On multivariate analysis, PTV was among the factors predicting OS [15]. Long-term results of the RTOG 0617 trial have confirmed smaller PTV as a prognostic factor for better OS in inoperable stage III NSCLC treated with concurrent CRT [16].

Retrospective mono-institutional analyses of conventional CRT in inoperable stage III NSCLC revealed a PTV cut-off of 700ccm to have a significant impact on patient survival [17, 18].

In the PACIFIC trial, patients with inoperable stage IIIB disease (UICC 7th edition) were equally distributed between the durvalumab (44.5%) and placebo (45.1%) arm, however this trial did not provide any information about the impact of PTV on patient outcome [5, 9, 10, 22]. Shaverdian et al. [23, 24] reported no impact of PTV on patient eligibility for durvalumab maintenance therapy after CRT and no effect of PTV on the onset of pneumonitis during a durvalumab maintenance therapy.

Two studies on CRT combined with concurrent and/or sequential anti-PD-1 inhibitors (LUN 14–179 and NICO-LAS) reported a significantly lower PFS and OS in patients with UICC 7th edition stage IIIB disease [6, 7, 25, 26]. In our study, the subgroup of patients with both PTV $\geq$ 900ccm
and stage IIIC disease (UICC 8th edition) had a very short PFS and eMFS despite successfully completed trimodal therapy.

Considering the apparent limitations of our analysis, namely its single-center design, limited patient number and a median follow-up of 19.9 months, it is of potential interest

**Table 3** Outcome for PTV < 900ccm vs PTV ≥ 900ccm and results of the univariate analysis

| Months after CRT | OS in % < // ≥ 900ccm | PFS in % < // ≥ 900ccm | LRPFS in % < // ≥ 900ccm | eMFS in % < // ≥ 900ccm | BMFS in % < // ≥ 900ccm |
|------------------|------------------------|------------------------|---------------------------|--------------------------|-------------------------|
| 3                | 100/100                | 100/83                 | 100/100                   | 100/83                   | 100/100                 |
| 6                | 100/100                | 93/60                  | 100/100                   | 93/60                    | 100/100                 |
| 9                | 100/100                | 85/40                  | 96/80                     | 89/40                    | 96/80                   |
| 12               | 96/80                  | 77/20                  | 88/60                     | 85/20                    | 88/60                   |
| 15               | 92/80                  | 56/20                  | 75/50                     | 72/20                    | 79/60                   |
| p-values for PTV < // ≥ 900ccm (log-rank) | 0.415                  | 0.020                  | 0.064                     | 0.003                    | 0.296                   |
| p-values for PTV as a continuous variable (cox regression) | 0.245                  | 0.129                  | 0.108                     | 0.048                    | 0.653                   |

**Fig. 3** Kaplan–Meier curves of extracranial distant metastasis-free (eMFS) for all patients stratified according to the planning target volume (PTV)
to re-evaluate these findings in a larger patient collective to confirm an impact of PTV on the course of disease and long-term patient outcome.

In summary, the present results show a significant deterioration of PFS and eMFS in inoperable stage III NSCLC patients with very large PTV (≥900ccm). This negative effect was more pronounced in patients with stage IIIC disease (UICC 8th edition). Our findings suggest a potential role for induction treatment in this subgroup of patients. Several studies investigating induction therapy for definitive CRT combined with concurrent and/or sequential CPI are ongoing or planned [27–31].

Conclusion

The present study revealed that PTV ≥900 cc has a significant impact on PFS and eDMFS in inoperable stage III NSCLC patients treated with definitive CRT combined with concurrent and/or sequential CPI.

Author Contributions Data curation: Julian Taugner, Lukas Käsmann; Formal analysis, Julian Taugner and Lukas Käsmann; Investigation, Lukas Käsmann, Chukwuka Eze and Farkhad Manapov; Methodology, Claus Belka and Farkhad Manapov; Project administration, Claus Belka; Resources, Chukwuka Eze, Amanda Tufman and Claus Belka; Supervision, Farkhad Manapov; Writing –original draft, Julian Taugner and Lukas Käsmann; Writing –review & editing, Lukas Käsmann, Monika Karin, Benedikt Flörsch, Julia Guggenberger, Minglun Li, Chukwuka Eze, Amanda Tufman, Niels Reinmuth, Thomas Duell, Claus Belka and Farkhad Manapov.

Funding Open Access funding enabled and organized by Projekt DEAL. This study was supported by the Munich Excellence Training Initiative for Physician Scientists (Metiphys to LK). The research was conducted without external funding.

Data availability The data that support the findings of this study are available from the corresponding author, upon reasonable request.

Declarations

Ethics approval and consent to participate All patients provided signed informed consent. The study was approved by the Institutional Review Board of the University hospital of the Ludwig-Maximilians-University (approval number: 17–230) and was conducted according to local and federal regulations and the Declaration of Helsinki.

Informed consent All study participants provided written informed consent. Informed consent was obtained from all individual participants included in the study.

Research involving human participants and/or animals All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its subsequent amendments or comparable ethical standards. This research did not involve any animal research.

Conflict of interests The authors declare no conflict of interest. Farkhad Manapov receives an Institutional research grant for participating or running clinical studies from Astrazeneca (outside of the study mentioned in the manuscript).

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA A Cancer J Clin 69(1):7–34. https://doi.org/10.3322/caac.21551
2. Taugner J, Eze C, Käsmann L et al (2020) Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer. Radiat Oncol 15(1):148. https://doi.org/10.1186/s13046-020-01590-8
3. Käsmann L, Taugner J, Eze C et al (2019) Performance Status and Its Changes Predict Outcome for Patients With Inoperable Stage III NSCLC Undergoing Multimodal Treatment. Anticancer Res 39(9):5077–5081. https://doi.org/10.21873/anticancerres.13701
4. Taugner J, Käsmann L, Eze C et al (2019) Survival score to characterize prognosis in inoperable stage III NSCLC after chemoradiotherapy. Transl Lung Cancer Res 8(5):593–604. https://doi.org/10.21037/tlcr.2019.09.19
5. Antonia SJ, Villegas A, Daniel D et al (2017) Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med 377(20):1919–1929. https://doi.org/10.1056/NEJMoa1709937
6. Peters S, Felip E, Dafni U et al (2019) Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemoradiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial. Lung Cancer 133:83–87. https://doi.org/10.1016/j.lungcan.2019.05.001
7. Peters S, Felip E, Dafni U et al (2020) Progression-free and overall survival for concurrent nivolumab with standard concurrent chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: Results from the European Thoracic Oncology Platform NICOLAS phase II trial (EOP 6–14). J Thorac Oncol. https://doi.org/10.1016/j.jtho.2020.10.129
8. Käsmann L, Eze C, Taugner J et al (2020) Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy. Radiat Oncol 15(1):167. https://doi.org/10.1186/s13046-020-01595-3
9. Antonia SJ, Villegas A, Daniel D et al (2018) Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med 379(24):2342–2350. https://doi.org/10.1056/NEJMoa1809697
10. Gray JE, Villegas A, Daniel D et al (2020) Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III
Investigational New Drugs (2022) 40:163–171

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.